Needham & Company increased its target price and gave a buy rating for MoonLake Immunotherapeutics.
1 report, 1 independent
Updated Jul 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Needham & Company increased its target price and gave a buy rating for MoonLake Immunotherapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Needham & Company
American independent investment bank and asset management firm
Related events
- Needham & Company increased its target price on Stagwell, while MarketBeat provided consensus rating data.
- MarketBeat provided average ratings and consensus target prices for Pacira BioSciences, while Needham and Royal Bank of Canada issued rating updates.
- Needham & Company lowered its target price for Fabrinet on October 31, 2026.
Coverage
Newest first; wire copies grouped- themarketsdaily.comRice Hall James & Associates LLC Buys 40,301 Shares of MoonLake Immunotherapeutics $MLTX